Paper36968218
Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.
Seidensticker M and 18 others. JHEP Rep, 2023. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial. Papers, record 36968218. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36968218
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01126645 | Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer | Derived from the trial | Yes |
Source ClinicalTrials.gov
References19
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32352320 | IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. | Future Oncol | 2020 | https://conductscience.org/library/papers/32352320 | PubMed |
| 2 | 33103093 | Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. | JHEP Rep | 2020 | https://conductscience.org/library/papers/33103093 | PubMed |
| 3 | 17522506 | A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. | Ann Surg | 2007 | https://conductscience.org/library/papers/17522506 | PubMed |
| 4 | 22004366 | Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis. | J Gastroenterol Hepatol | 2012 | https://conductscience.org/library/papers/22004366 | PubMed |
| 5 | 34801630 | BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. | J Hepatol | 2022 | https://conductscience.org/library/papers/34801630 | PubMed |
| 6 | 34243077 | Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). | Eur J Cancer | 2021 | https://conductscience.org/library/papers/34243077 | PubMed |
| 7 | 17133492 | Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. | Hepatology | 2006 | https://conductscience.org/library/papers/17133492 | PubMed |
| 8 | 29503247 | Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. | Lancet Gastroenterol Hepatol | 2018 | https://conductscience.org/library/papers/29503247 | PubMed |
| 9 | 23023956 | Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. | Br J Surg | 2012 | https://conductscience.org/library/papers/23023956 | PubMed |
| 10 | 31421157 | Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. | J Hepatol | 2019 | https://conductscience.org/library/papers/31421157 | PubMed |
| 11 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 12 | 21574174 | Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. | Hepatology | 2011 | https://conductscience.org/library/papers/21574174 | PubMed |
| 13 | 19095497 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. | Lancet Oncol | 2009 | https://conductscience.org/library/papers/19095497 | PubMed |
| 14 | 22634125 | A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. | J Hepatol | 2012 | https://conductscience.org/library/papers/22634125 | PubMed |
| 15 | 24728665 | Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. | J Gastroenterol | 2015 | https://conductscience.org/library/papers/24728665 | PubMed |
| 16 | 26361969 | Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/26361969 | PubMed |
| 17 | 25064436 | Increased survival in hepatocellular carcinoma with iodine-125 implantation plus radiofrequency ablation: a prospective randomized controlled trial. | J Hepatol | 2014 | https://conductscience.org/library/papers/25064436 | PubMed |
| 18 | 29628281 | EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. | J Hepatol | 2018 | https://conductscience.org/library/papers/29628281 | PubMed |
| 19 | 25284802 | Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. | Hepatology | 2015 | https://conductscience.org/library/papers/25284802 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42882822 | Adjuvant and Perioperative Systemic Therapy for Resectable Hepatocellular Carcinoma: Evidence, Biological Rationale, and Trial Design. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882822 | PubMed |
| 41892200 | The State of the Art in Combination Locoregional and Systemic Treatment Strategies for Hepatocellular Carcinoma: Recent Advancements and Future Horizons. | Curr Oncol | 2026 | https://conductscience.org/library/papers/41892200 | PubMed |
| 41695324 | Traditional Cox regression outperforms large language models in predicting long-term progression of intermediate to advanced hepatocellular carcinoma. | Front Oncol | 2026 | https://conductscience.org/library/papers/41695324 | PubMed |
| 41263849 | Individualised dosimetry for holmium-166 RE in patients with unresectable hepatocellular carcinoma; a multi-centre, interventional, non-randomised, non-comparative, open label, phase II study: RHEPaiR. | BMJ Open | 2025 | https://conductscience.org/library/papers/41263849 | PubMed |
| 40573279 | The Efficacy of Combined Use of Huaier Granules in the Treatment of Primary Liver Cancer: An Updated Systematic Review and Meta-Analysis. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40573279 | PubMed |
| 40568833 | Sorafenib with or without co-interventions for hepatocellular carcinoma. | Cochrane Database Syst Rev | 2025 | https://conductscience.org/library/papers/40568833 | PubMed |
| 40445470 | Modern therapeutic approaches for hepatic tumors: progress, limitations, and future directions. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40445470 | PubMed |
| 39759148 | Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma. | Front Oncol | 2024 | https://conductscience.org/library/papers/39759148 | PubMed |
| 39579154 | Evaluation of a deformable image registration algorithm for image-guided thermal ablation of liver tumors on clinically acquired MR-temperature maps. | Med Phys | 2025 | https://conductscience.org/library/papers/39579154 | PubMed |
| 39561966 | Hepatocellular carcinoma systemic treatment update: From early to advanced stage. | Biomed J | 2025 | https://conductscience.org/library/papers/39561966 | PubMed |
| 39143267 | Accuracy of 3D real-time MRI temperature mapping in gel phantoms during microwave heating. | Eur Radiol Exp | 2024 | https://conductscience.org/library/papers/39143267 | PubMed |
| 38405324 | Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions? | J Hepatocell Carcinoma | 2024 | https://conductscience.org/library/papers/38405324 | PubMed |
| 37568804 | Early-Stage HCC Percutaneous Locoregional Management: East versus West Perspectives. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37568804 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36968218
GET https://conductscience.org/api/papers/v1/36968218/authors